Reagents and instruments for immunology, cell biology and molecular biology.
 

Abbexa

 

Abbexa is a dedicated worldwide supplier of biological tools for the life science, pharmaceutical and biotechnology research and development sectors. Abbexa provides the scientific community with primary antibodies, secondary antibodies, proteins, ELISA kits and enzymes as well as other kits and tools designed for use in research. Abbexa also offers custom protein, peptide and antibody production services to meet customer requirements.

Abbexa is committed to providing scientists and researchers with the best customer experience and high-quality products.

Abbexa’s mission is to offer unrivalled expertise and outstanding quality laboratory consumable products, striving to consistently improve. Please do get in touch with any comments regarding the website, service, products, or anything else.

 

Learn more :

 

 

  

  

 

 

         

   

  

Antibodies for Cancer Research

     

Cell Biology Antibodies

    

ELISA Kits for Accurate Detection

   Primary Antibodies
             

 

 

Website : www.abbexa.com
 
 
> Abbexa > Products for research > COVID-19 > SARS-CoV-2 - Therapeutic Candidates for Research and Development > SARS-CoV-2 - Baricitinib - Therapeutic Candidates
SARS-CoV-2 - Baricitinib - Therapeutic Candidates

SARS-CoV-2 - Baricitinib - Therapeutic Candidates


Like ruxolitinib, baricitinib (OLUMIANT) is an inhibitor of Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2) which are tyrosine kinases involved in JAK signaling pathways. Baricitinib is a reversible and selective inhibitor and is indicated in the treatment of moderate to severe active rheumatoid arthritis for its anti-inflammatory effect. It is a second-line therapy, i.e., used after failure of conventional disease-modifying therapies. It can be used alone or in combination with methotrexate (MTX).
A clinical study on the efficacy and safety of baricitinib for the treatment of Covid-19 has begun. The anti-inflammatory activity of this drug may have a potential beneficial effect in the treatment of Covid-19. The use of baritinicib therapy may limit the cytokine release syndrome associated with Covid-19 and may be useful because it acts against a wide range of cytokines.

Search result : 2 product found

Refine your search :

RUOCE / IVD
  • Biochemicals 2
APPLY FILTERS
REINITIALIZE


Cat#
Description
Cond.
Price Bef. VAT
abx076867-25mg
Baricitinib
 25mg 
abx076867-5mg
Baricitinib
 5mg 
    ‹
    ›